Molecular profiling in diffuse large B‐cell lymphoma: why so many types of subtypes? by Morin, Ryan D. et al.
Molecular profiling in diffuse large B-cell lymphoma: why so
many types of subtypes?
Ryan D. Morin,1,2,3 Sarah E. Arthur1,3 and Daniel J. Hodson4,5
1Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, 2Genome Sciences Centre, BC Cancer,
Vancouver, BC, 3BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, 4Wellcome MRC Cambridge Stem Cell Institute, Cam-
bridge Biomedical Campus, Cambridge, and 5Department of Haematology, University of Cambridge, Cambridge
Summary
The term diffuse large B-cell lymphoma (DLBCL) includes a
heterogeneous collection of biologically distinct tumours.
This heterogeneity currently presents a barrier to the success-
ful deployment of novel, biologically targeted therapies.
Molecular profiling studies have recently proposed new
molecular classification systems. These have the potential to
resolve the biological heterogeneity of DLBCL into manage-
able subgroups of tumours that rely on shared oncogenic
programmes. In many cases these biological programmes
straddle the boundaries of our existing systems for classifying
B-cell lymphomas. Here we review the findings from these
major molecular profiling studies with a specific focus on
those that propose new genetic subgroups of DLBCL. We
highlight the areas of consensus and discordance between
these studies and discuss the implications for current clinical
practice and for clinical trials. Finally, we address the out-
standing challenges and solutions to the introduction of
genomic subtyping and precision medicine in DLBCL.
Keywords: lymphomas, diffuse large B-cell lymphoma, can-
cer genetics, mutation analysis, classifications.
Diffuse large B-cell lymphoma (DLBCL) is an aggressive
non-Hodgkin lymphoma and the commonest lymphoid
malignancy.1 First-line therapy with immunochemotherapy
regimens such as cyclophosphamide, doxorubicin, vincristine,
prednisone + rituximab (R-CHOP) now cures up to 60% of
patients. However, those failing first-line therapy present a
significant clinical challenge and a majority of these patients
still die from their disease. To address this need, the molecu-
lar pathogenesis of DLBCL has been the focus of intense
study. The extent of new biological and genetic understand-
ing that has been amassed in recent years is remarkable. It
has highlighted multiple targetable oncogenic pathways and
launched the development of a plethora of promising novel
therapeutic agents. However, this excitement has been tem-
pered by more sobering statistics; since R-CHOP was intro-
duced in 2002,2 numerous phase-three trials have examined
modifications or additions to R-CHOP as first-line therapy
for DLBCL. Many have examined the use of promising novel
therapeutic agents.3–8 However, none of these trials has met
its primary end-point and first-line therapy for DLBCL has
remained unchanged for almost two decades.2 Although the
promise of molecularly targeted therapy in DLBCL may be
more elusive than we had hoped, one can also view this as
an opportunity to re-assess the design of clinical trials to
increase our chances of future improvements to clinical man-
agement.
The greatest barrier to the successful introduction of tar-
geted therapy in DLBCL is the diversity of genetic features
and phenotypes within this clinical entity. It continues to
become clear that DLBCL is not a single disease but a collec-
tion of diseases, each with defining molecular and biological
features. The full repertoire of distinguishable entities that
comprise this spectrum are beginning to be described but
remains far from fully resolved. Since each entity may rely
on distinct oncogenic pathways it is reasonable to assume
that novel therapies designed to inhibit specific oncogenic
pathways may have activity only in certain subgroups and
therefore may show little detectable activity if used in a blan-
ket approach. Recent molecular profiling studies provide us
with a handle to rationalise this biological heterogeneity into
more homogeneous subgroups of DLBCL. It is premature to
consider that knowledge of these subtypes can direct the
optimal treatment for an individual patient. However, it pro-
vides a framework on which to design and interpret the
results of future clinical trials.
Existing strategies for molecular profiling of
DLBCL
The first insight into the molecular heterogeneity of DLBCL
arose from the application of gene expression profiling using
microarray technology.9 This showed that DLBCL could be
divided into two groups with distinct gene expression
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patterns; one resembling normal germinal-centre B cells and
another sharing features with blood B cells activated in vitro.
These transcriptional subtypes became known as germinal-
centre (GCB) and activated B cell (ABC) respectively. A sta-
tistical approach was later developed to rank DLBCLs based
on their expression of these genes and assign them proba-
bilistically into one of these two groups, leaving a small
number of cases unclassified (UC).10 Although it had not
been established that these classes originated from distinct
cell types, this classification system became known as cell of
origin (COO). A number of implementations of COO classi-
fiers have since been developed that could be applied to
microarray, RNA-Seq or more focused gene expression mea-
surements including NanoString or HTG EdgeSeq technol-
ogy.11–13 The requirement for sophisticated transcriptional
profiling technology initially limited the utility of COO pro-
filing to research applications. Attempts to reproduce the
COO transcriptional classification in a standard diagnostic
setting by scoring surrogate protein markers with immuno-
histochemistry met with variable success,14,15 but at best were
able to offer a binary classification of GCB or non-GCB that
imperfectly recapitulated the transcriptional classification.
Initial excitement for this stratification related to the
observation that patients with ABC DLBCL had, on average,
a worse prognosis than GCB DLBCLs.11,16 However, perhaps
the most significant consequence of the COO classification
was to provide a framework on which to build our under-
standing of DLBCL biology. Indeed, the experimental com-
parison of ABC and GCB biopsies and cell lines has allowed
us to dissect critical oncogenic pathways unique to each sub-
type.17 In contrast, its contribution to routine clinical prac-
tice has been more limited and COO was not incorporated
into the revised WHO classification of DLBCL until 2016.18
Although there are numerous therapies targeting genetic fea-
tures that are strongly associated with only one COO, there
is currently no compelling evidence to suggest that ABC and
GCB patients receive benefit from different treatments up-
front or in the relapse setting.
An alternative strategy to subclassify DLBCL is based upon
the detection of rearrangement of MYC, BCL2 and/or BCL6
by fluorescent in-situ hybridisation (FISH), a technique rou-
tinely available in diagnostic laboratories. These double/triple
translocated cases are now assigned to a new diagnostic
entity that is currently considered distinct from DLBCL in
the 2016 revised WHO classification.18 This is termed high-
grade B-cell lymphoma with MYC and BCL2 and/or BCL6
rearrangements, or HGBL-DH/TH (also commonly referred
to as double-hit or triple-hit lymphoma), which can also
include tumours that do not have DLBCL morphology.
However, it remains far from clear that the detection of
MYC and BCL2/BCL6 rearrangements identifies a biologically
homogeneous lymphoma subtype. The impetus for this clas-
sification was driven in part by the perceived impact on
prognosis; initial retrospective series suggested a dismal sur-
vival amongst lymphomas with rearrangement of both MYC
and BCL2.19,20 However, this may partially reflect the initial
preferential testing of high-risk cases as subsequent prospec-
tive clinical trials have confirmed a definite but more modest
negative prognostic impact.21,22 The negative prognostic
impact of double-hit lymphoma (DHL) may be restricted to
those cases with translocation between MYC and the
immunoglobulin loci rather than other rearrangement part-
ners, a distinction that may not be discernible in all routinely
used FISH assays but can be revealed by dual-fusion probe
assays.22 This situation is further confounded by the exis-
tence of pseudo-double-hit lymphoma, specifically those with
t(3;8)(q27;24), which are indistinguishable from separate
BCL6 and MYC translocations by break-apart FISH.23 Many
centres have adopted intensified immunochemotherapy
approaches for double-hit patients based on retrospective
studies.24,25 However, this approach has never been tested in
a prospective, randomised setting. This widespread adoption
now acts as a barrier to a randomised trial and is a situation
we should endeavour to avoid repeating as emerging genetic
subtypes become incorporated into clinical practice.
More recently, two groups used complementary gene
expression approaches to identify MYC-driven subtypes of
DLBCLs. One of the signatures was derived from the subset
of DHL with MYC and BCL2 translocations. These cases
were almost all GCB by COO profiling and termed the
‘double-hit signature’ (DHITsig).26 The other study used a
Burkitt lymphoma signature to identify ‘Molecular High-
Grade’ (MHG) lymphomas.27 Both of these signatures iden-
tify MYC-driven DLBCL cases that overlap only partially
with HGBL-DH/TH. For example, approximately half of
tumours classified as DHITsig+ lack one of the expected
oncogene rearrangements by FISH (e.g., BCL2 or MYC).
More thorough genetic characterisation of such cases
revealed frequent cryptic rearrangements of the MYC or
BCL2 loci.28 These two related transcriptional subgroups
have clinical relevance because DHITsig/MHG tend to repre-
sent a subgroup of GCB DLBCLs with an inferior survival
relative when treated with R-CHOP. Whether intensified or
other therapy would benefit this group of patients remains to
be determined. Figure 1 provides a high-level overview of the
variety of assays in use for research and clinical application
for lymphoma diagnosis and subclassification.
Genomic profiling of DLBCL
Initial unbiased genome and exome-wide sequencing studies
reaffirmed the biological distinctions between ABC and GCB
DLBCLs as well as revealing the genetic similarities between
GCB DLBCL and follicular lymphoma.29–33 Many recurrently
mutated genes were specific to B-cell lymphoma, suggesting
biology distinct from that of epithelial malignancies. Investi-
gation of the more frequent mutations revealed lymphoma-
specific oncogenic mechanisms such as the mutation of chro-
matin modifiers in GCB DLBCL and the B-cell receptor
(BCR) pathway in ABC DLBCL.34,35 As larger numbers of
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patients were sequenced the genomic complexity of DLBCL
became increasingly apparent.36 In contrast to other haema-
tological malignancies, DLBCL shows a greater number of
mutations per patient and a larger number of recurrently
mutated genes, with a long tail of genes mutated in only a
small number of cases. Overall, the field has now converged
onto approximately 150 protein-coding driver genes that are
recurrently mutated or functional targets of somatic copy
number alterations in DLBCL. Whilst the majority of these
genes are mutated in only a minority of patients it became
clear that these mutations were not randomly distributed.
For example, cases with mutant MYD88 were more likely to
carry a mutation of CD79B. In contrast, cases with BCL2
translocation are enriched for CREBBP and EZH2 mutations.
This suggested that mutations might cluster into functional
groups that could represent biological subtypes of DLBCL.
To pursue this concept, Staudt and colleagues at the
National Cancer Institute (NCI) performed transcriptional
profiling, whole-exome sequencing, targeted mutation
sequencing and array-based copy number analysis on 574
cases of DLBCL.37 They identified the most enriched combi-
nations of genetic alterations in each transcriptional subtype
of DLBCL and found patterns of genetic features that
extended beyond the two main COO subgroups. They
devised a set of subdivisions or genetic subgroups named
after the most common distinguishing features of each
group. One of these was characterised by MYD88 and CD79B
mutations (MCD) and strongly associated with ABC
DLBCLs. Another was enriched for EZH2 mutation and
BCL2 translocation (EZB) and was prototypical of GCB
DLBCL. Stemming from an observation that BCL6 structural
alterations and NOTCH2 mutations were enriched among
cases unclassifiable by COO, a third group (BN2) was pro-
posed. They also noticed a small number of ABC patients
with mutations in NOTCH1 that were mutually exclusive
with other ABC or NOTCH2 mutations and were considered
a separate group (N1). Just over half of patients remained
UC suggesting further subtypes remained to be described. A
summary of the genetics of the NCI cohort and their rela-
tionship to COO is shown in Fig 2.
Concurrent with this work, Shipp and colleagues at Har-
vard applied a data-driven clustering strategy to mutational
and copy number data derived from whole-exome and tar-
geted sequencing of 304 DLBCLs.38 In contrast to the NCI
study, the Harvard group relied on an unsupervised consen-
sus clustering method. This resolved patients into five clus-
ters that mathematically shared the most similar repertoires
of genetic alterations. These clusters were termed C1–C5.
Despite the distinct statistical approach, considerable overlap
with the NCI findings were apparent; the C1 cluster,
enriched for BCL6 fusion and NOTCH2 mutation corre-
sponded clearly to the BN2 group. The C3 cluster, enriched
for translocation of BCL2 and mutation of CREBBP and
EZH2 clearly corresponded to the EZB group. The C5 clus-
ter, enriched for MYD88 and CD79B mutations aligned to
the MCD group. However, two new clusters emerged. C2
was dominated by mutation of TP53 and widespread copy
number alteration. C4 was enriched for somatic hypermuta-
tion of SGK1 and genes encoding histone linker proteins. A
tiny fraction of patients (4%) with no detectable mutations
were categorised as C0.
A follow-up paper from the NCI then examined further
cases not classified in their original publication.39 They noted
that these were enriched for tumours with high levels of ane-
uploidy and mutation of TP53. A second enrichment was
seen for cases with mutation of SGK1 and TET2. These
genetic features were used to seed the clustering of two new
subtypes termed A53 (aneuploidy, TP53) and ST2 (SGK1,
TET2). These corresponded closely to the Harvard C2 and
C4 clusters. Thus, each of the five Harvard clusters could
Fig 1. Molecular profiling for personalised medicine. An idealized personalised medicine workflow illustrating the diversity of sample and nucleic
acid types that might be subjected to an equally diverse selection of molecular assays with the goal of aiding selection of the most appropriate
therapeutic.
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now be mapped to one of the NCI genetic subgroups. How-
ever, there remained substantial discrepancies in how cases
are assigned to each of the corresponding subgroups and a
notable difference between studies was that over 40% of cases
remained UC or genetically composite in the NCI study. The
genetic classification system developed by the NCI became
known as LymphGen and was released as a publicly available
tool that can be applied to classify an individual case. A
comparison of the genetics and classification strategies of the
NCI (LymphGen) and Harvard studies is presented in Fig 3.
Finally, a study from the UK Haematological Malignancy
Research Network (HMRN) applied targeted sequencing of
293 genes to DNA extracted from archived formalin-fixed
paraffin-embedded (FFPE) biopsies from 928 cases of
DLBCL.40 Sequencing data were subjected to unsupervised
clustering using a Bernoulli mixture modelling strategy.
Fig 2. Classification of National Cancer Institute (NCI) cases using LymphGen genetic classifier. This oncoprint shows the mutation status of
patients sequenced in the NCI study.37 Each column represents a single patient. Selected key genes with the greatest impact on classification are
shown. Different mutation types are indicated with a distinct colour. The assignment of cell of origin (COO) of cases is shown below the onco-
print. The LymphGen genetic classifier was used to classify each patient as shown by coloured bars at the figure base. The figure highlights impor-
tant features of the LymphGen classification system. Firstly, a substantial fraction of cases remains unclassified or are assigned to more than one
class. These ‘composite’ cases have a sufficient representation of genetic features from more than one class such that their classification is more
ambiguous. A simplified classification (LymphGenSimple) is also presented whereby composite cases are assigned to a single class by selecting
only one of the assigned classes using a prioritized set of classes.
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Clustering was based predominantly on mutation data, with
copy number alterations considered only for a small number
of genes. Translocation and gene fusion data were not avail-
able for all cases and were therefore excluded from the clus-
tering. Therefore, this study differed from the NCI and
Harvard studies in several respects: the sequencing strategy
used, the types of the genetic data seen by the clustering
algorithms, and the statistical approach employed to identify
clusters. Despite this, genetic subtypes emerged that could be
mapped almost precisely to NCI and Harvard categories.
These were named according to the most enriched genetic
feature. The group termed MYD88 recapitulated the MCD/
C5 clusters. The BCL2 group corresponded to EZB/C3. A
NOTCH2 group mapped to the BN2/C1 clusters. Finally, an
SGK1 group reproduced the ST2/C4 clusters. Perhaps owing
to the greater number of cases in the HMRN study, the
SGK1 group was split into SOCS1/SGK1 and TET2/SGK1.
Overall, 27% of cases remained UC. Neither a NOTCH1
mutant group or a A53/C2 equivalent group were identified.
In fact, the frequency of N1 cases (17% of all DLBCL in the
NCI study) was too low to be resolvable as a distinct cate-
gory in unsupervised clustering, whereas limited copy num-
ber data precluded identification of an A53/C2 group in the
HMRN study. However, rather than being classified else-
where, both TP53 and NOTCH1 mutant patients were prin-
cipally enriched amongst the UC cases suggesting their
absence should not be considered as evidence against the
validity of these groups. A further modification of the
HMRN classification used the presence of MYC hotspot and
NOTCH1 PEST domain mutations to identify a NOTCH1
and BCL2-MYC subgroups.41 This modified HMRN classifier
showed high concordance when cases were reclassified using
the NCI LymphGen classifier (Fig 4).
It is encouraging that studies with different sequencing
and computational approaches independently converge on a
remarkably similar system for the genetic classification of
DLBCL. The degree of consensus provides strong evidence
for the validity of genetically defined, biological subtypes of
DLBCL. Gene expression profiling offers further support that
each subtype relies on fundamentally different biological
pathways.37,40 A comparison across studies and the salient
feature of each subtype are summarised in Table I. For con-
sistency we will adopt the NCI (LymphGen) nomenclature
throughout the remainder of this study, unless referring to
subgroups from a specific study. Ultimately, genetic classifi-
cation provides a means to rationalise the genetic hetero-
geneity of DLBCL into subgroups that share a common
biological pathogenesis and may therefore respond similarly
to specific therapies. We anticipate that robust publicly avail-
able methods to assign DLBCLs to these subgroups will
emerge as their definition continues to be refined. This,
therefore, begins to address one of the biggest barriers to the
introduction of targeted therapies or precision medicine to
the treatment of DLBCL.
Superimposing the biology of genetic subtypes
onto other known lymphoma entities
Examining the mutational repertoires of individual subtypes
provides clues to the biology and reveals unexpected overlap
with other categories of lymphoma distinct from DLBCL
(Figs 5 and 6, Table I). MCD tumours have the strongest
ABC expression signature and are characterised by mutations
that activate BCR and toll-like receptor pathways, both of
which converge onto increased nuclear factor kappa B
(NFKB) activity.42–44 Other frequent genetic alterations
include amplification of the BCL2 locus, deletion of the cell
cycle negative regulator CDKN2A, and mutations that con-
verge upon immune evasion.39 Almost all cases show the
transcriptional profile of ABC DLBCL including increased
signatures of NFKB and MYC activity.37,40 The genetic fea-
tures of MCD overlap strongly with those reported in the
extranodal lymphomas, including primary central nervous
system lymphoma (PCNSL), primary breast lymphoma and
primary testicular lymphoma (PTL).45–47 Indeed, cases of
PCNSL and PTL included in the above clustering studies
almost all clustered into the MCD subtype (Fig 5B). Recent
single-cell analysis of normal lymph nodes suggests a sub-
stantial proportion of MCD lymphoma may arise from a dis-
tinct pre-memory B-cell stage of post-germinal-centre B-cell
development (Fig 6).48 This finding resonates with the fre-
quent mutation of TBL1XR1 in MCD DLBCL, since
TBL1XR1 mutations in mouse models promote memory B-
cell expansion and extranodal lymphoma.49 Overall, this sug-
gests MCD DLBCL is a distinct form of DLBCL that, from a
biological perspective, overlaps more strongly with PCNSL
and PTL than it does with other forms of DLBCL not other-
wise specified (NOS). The recurrent mutation of BCR and
immune pathway genes within this subtype leads to hypothe-
ses about potential therapeutic vulnerabilities that may be
tested in future clinical trials of BCR or immune checkpoint
inhibition.
At the other end of the biological spectrum, EZB tumours
are strongly enriched for GCB DLBCLs. They are charac-
terised by translocation of BCL2 into the immunoglobulin
locus, and mutation of histone modifiers such as KMT2D,
EZH2, CREBBP and EP300. Mouse models have shown how
mutations of these genes lead to a block of differentiation
and sustained expression of the germinal-centre transcrip-
tional programme, which co-operate with BCL2 to drive
lymphomagenesis.50–58 The mutation profile of EZB matches
closely to that seen in follicular lymphoma (FL).29,33,59,60 The
HMRN study showed that DLBCLs that had transformed
from FL were strongly enriched in this cluster (Fig 5B).40
The shared genetic features of transformed FL and EZB
DLBCL is consistent with the notion that so-called de novo
cases of EZB DLBCL and FL may both arise from a common
origin (Fig 6).40 Indeed, the HMRN study revealed that 27%
of cases assigned to this subtype had evidence of previously
Review
ª 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. 5
Review
6 ª 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
undiagnosed FL discovered on lymph node or trephine
biopsy concurrent with the diagnosis of DLBCL.40 This leads
us to speculate that a substantial proportion of de novo
DLBCLs of the EZB class may arise via transformation from
an occult FL.
The EZB subtype also appears to be the primary genetic
background of DHL. The HMRN study showed how HGBL-
DH/TH cases (identified by FISH) were found predomi-
nantly within this subtype, as were the transcriptionally iden-
tified MHG cases.40 Similarly, the NCI study used the closely
related DHITsig transcriptional signature to reveal enrich-
ment of DHITsig+ cases within the EZB subtype.39 This sug-
gests the existence of a subgroup of aggressive, MYC-driven
lymphomas within the EZB cluster that represents a distinct
disease entity that may arise from germinal-centre dark-zone
centroblasts (Fig 6). It also suggests that MYC or BCL2 sin-
gle or doubly rearranged cases from other genetic subtypes
may not necessarily have the same clinical or biological
implications. In the NCI LymphGen classification system,
EZB is further subdivided into EZB–MYC+ and EZB–MYC
to differentiate cases with and without either MYC rear-
rangement or the DHITsig gene expression signature. Simi-
larly, in a modification to the original HMRN classification
(modified HMRN), the presence of MYC hotspot mutations,
which are known to correlate strongly with rearrangement
status,61 were used to define MYC-driven cases within the
BCL2 subgroup.41 Notably, tissue collection in most of the
above studies occurred prior to the WHO revision to lym-
phoid classification which introduced the category of high-
grade B-cell lymphoma with MYC and BCL2 and/or BCL6
rearrangements. These new genetic findings challenge the
utility of this WHO disease category as a meaningful, homo-
geneous biological entity and motivate the revision of this
definition.
The BN2 subgroup does not have unifying gene expression
features and represents a mix of ABC, GCB and UC cases.
BN2 is enriched for BCL6 fusion and mutation of NOTCH2
and other NOTCH pathway genes. Interestingly, transcrip-
tional signatures of NOTCH activation were not identified in
these tumours,37,40 suggesting that the activating NOTCH2
mutations may exert their effect at a specific stage of lym-
phoma development. Other mutations enriched in the BN2
cluster appear to activate NFKB; these include loss of
TNFAIP3, gain of BCL10 and 3ʹ-untranslated region (3ʹUTR)
mutation (leading to enhanced expression) of NFKBIZ.62
Many of these genetic alterations, especially NOTCH2 muta-
tion, are reminiscent of marginal-zone lymphoma
(MZL).63,64 It is tempting to speculate that these lymphomas
arise from transformation of an underlying MZL (Fig 6).
However, evidence of pre-existing MZL was not identified in
the clustering studies.38,40 Nevertheless, it is clear that a
shared biological programme and likely a shared cellular ori-
gin may link these two diseases.
The ST2 subtype also shares genetic similarity to indolent
lymphoma — in this case nodular lymphocyte-predominant
Hodgkin lymphoma (NLPHL)65 but direct evidence of trans-
formation from the latter remains to be identified. Mutations
in this subtype (including SOCS1, DUSP2, STAT3 and
BRAF) may lead to activation of JAK/STAT and ERK sig-
nalling pathways, a suggestion supported by gene expression
signatures.40 SGK1 mutations may lead to hyperstable protein
isoforms that act in parallel to AKT in the PI3K pathway.66
In the HMRN study the SGK1 subtype was subdivided into
SOCS1/SGK1 and TET2/SGK1. The former shares genetic
overlap with primary mediastinal B-cell lymphoma, including
SOCS1, ITPKB, NFKBIE and CIITA.67,68 The SOCS1/SGK1
subtype was enriched for cases of PMBCL (Fig 5B); however,
the remaining cases did not show preferential mediastinal
involvement. This suggests that PMBCL, a tumour defined in
part by its restricted anatomical involvement, may share con-
siderable biological overlap with this subtype of nodal
DLBCL NOS. This supports previous descriptions of non-
mediastinal DLBCLs with gene expression features and genet-
ics reminiscent of PMBCL and we speculate that these con-
tribute, in part, to the SOCS1/SGK1 subgroup.69,70
The N1 subtype is dominated by mutations that remove
the degradation domain, and thereby activate the oncogene
NOTCH1. These mutations are rare in DLBCL overall (17%
and 24% in the NCI and HMRN studies respectively) but
are common in chronic lymphocytic leukaemia (CLL) and in
Richter’s syndrome.71,72 N1 cases reported in the clustering
studies do not appear to represent overt transformation of
CLL but seem to share common oncogenic programmes with
these diseases.
Finally, the A53 subtype is defined by widespread copy
number variation. Mutation or deletion of TP53 is enriched
Fig 3. Comparison of the National Cancer Institute (NCI) and Harvard clusters. (A) The frequency of mutations in key genes associated with dif-
fuse large B-cell lymphoma (DLBCL) genetic subgroups are compared between the NCI and Harvard cohorts for the four largest subgroups.
Whilst strong agreement is seen for some genes, such as those defining the BN2/C1 group, there is more variable consensus across other subtypes,
exemplified by genes such as TET2, BCL2 and SOCS1. (B) This oncoprint shows the genetic features of each class across three DLBCL cohorts
including the Harvard,38 NCI37 and a cohort of patients from British Columbia.74 LymphGen was applied to the genetic data from all three
cohorts and the classifications are shown with and without composite labels — LymphGen and LymphGenSimple respectively. (C) The alluvial
plot shows the relative proportion of cases from the Harvard cohort assigned to each class when reclassified by LymphGen. This reclassification
was done in two ways; with or without the A53 option enabled in the LymphGen classifier. Vertical ribbons represent individual cases and can be
followed from top to bottom. Notably, when the A53 class is available, a large number of cases switch classification from one of the core classes
to A53. The plot demonstrates relatively high consensus between the two classification systems when considering the core classes, but weaker con-
sensus over patients classified into the A53 and C2 clusters.
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but not exclusive to this subtype. Beyond TP53, very few
other coding mutations were enriched within this subtype
and tumours with prototypical mutations characteristic of
the other groups are commonly assigned A53 or composite
classes including A53. Other than sharing aneuploidy result-
ing from the loss of TP53, it is unclear whether a unifying
biology exists within this group. When Harvard cases are
reclassified using the LymphGen classifier it becomes clear
that the A53 and C2 classes show much less overlap than do
the other equivalent classes. The observation that many of
the cases classified as A53 are reclassified to one of the other
classes indicates that this classification may mask biology that
Fig 4. Comparison of the Haematological Malignancy Research Network (HMRN) and LymphGen classifications. (A) This oncoprint shows
patients from the HMRN study.40 The LymphGen classifier was applied to the same data, with the A53 option disabled due to lack of sufficient
copy number information. LymphGen and HMRN classifications are shown in the lower bar. The HMRN classification was modified as described
in Runge et al.41 to identify BCL2-MYC and NOTCH1 groups. (B) Alluvial plot showing comparison of modified HMRN and LymphGen classifi-
cations for individual cases from the HMRN study. It can be seen that cases classified by LymphGen are predominantly assigned to their equiva-
lent HMRN group. The main distinctions between LymphGen and HMRN are that the latter further subdivides ST2 into the TET2/SGK1 and the
SOCS1/SGK1 classes and has a higher classification, leaving fewer cases classified as ‘other’.
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would otherwise be revealed from other genetic features
(Fig 3). This suggests that the genetic identity A53/C2 is the
least robust of the genetic groups (Fig 3B).
The genetic heterogeneity within the diagnosis of DLBCL
NOS suggests it represents an assortment of diseases. How-
ever, comparison with other lymphoma types suggests that
the biology may straddle the boundaries between DLBCL
NOS and other lymphoma types defined by the current
World Health Organization classification system. Ultimately,
a biology-focused classification of aggressive B-cell lym-
phoma may redefine many of these boundaries.
Implications for prognosis
The molecular classification systems discussed above are
based principally upon grouping tumours with shared biol-
ogy. However, a separate question is whether genetic classifi-
cations provide us with prognostic information that could be
useful in guiding patient management. It is clear that clinical
factors remain a dominant factor determining prognosis. It is
also clear that clinical factors are not independently dis-
tributed across the genetic subtypes.40 Thus, care must be
taken when inferring the independent prognostic impact of
each subtype.
Whilst genetic subgroups may show differential responses
to targeted therapy in the future, all current information
relates to conventional immunochemotherapy. Each of the
studies discussed above examined the impact of genetic sub-
types on patient outcome. It is important to acknowledge
differences in the patient cohorts and the types of treatment
used. The Harvard study reported clinical outcomes on 259
patients treated with R-CHOP-like therapy and derived from
a combination of archived biopsy collections and the
RICOVER-60 trial of elderly DLBCL. The NCI study
reported clinical outcomes on 240 patients, enriched for ABC
DLBCL, treated with R-CHOP-like therapy and derived from
a combination of archived biopsy collections and the CALGB
50303 clinical trial. The HMRN study reported clinical data
on 690 patients from the HMRN registry, which prospec-
tively tracks outcomes of every new haematological malig-
nancy diagnosis made at a regional diagnostic referral centre.
The latter may escape the inevitable recruitment and selec-
tion biases implicit in clinical trial or pathological archives.
Finally, distinct from the previous studies, the HMRN study
also reported outcome for the 579 DLBCL patients treated
with full-dose R-CHOP. Comparison to patients treated with
R-CHOP-like regimens in the same study reveals the impor-
tance of this subtle distinction.40 A summary of five-year
overall survival (OS) outcomes by subtype across studies is
shown in Fig 7.
When comparing across studies some clear conclusions
can be drawn. First is the association of the ST2 subgroup
with a favourable outcome. It was associated with superior
survival in the NCI study (five-year OS 84%) and the Har-
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study, SOCS1/SGK1 was the subtype associated with the
highest OS (five-year OS 80%) in R-CHOP-treated patients
and the lowest hazard ratio, when adjusted for International
Prognostic Index (IPI). Therefore, clear consensus exists
around the favourable outcome in this genetic subtype. Con-
versely, consensus also exists around the poor outcome of
patients with the N1 subtype; five-year OS was 27% in the
NCI study39 and 40% using a modified HMRN classifica-
tion.41 Similarly poor survival was seen for EZB–MYC
patients identified by expression profiling in the NCI study
(five-year OS 48%)39 or BCL2-MYC cases in the HMRN
study (five-year OS 40%).41
The potential prognostic impact of the other groups is not
as clear. EZB patients had an intermediate outcome (five-
year OS 70%) in the NCI study, a good outcome in the
HMRN study (five-year OS 82%) but one of the poorest sur-
vivals (five-year OS 60%) in the Harvard study (Fig 7). The
MCD subtype had an extremely poor survival in the NCI
study (five-year OS 40%). However, in the Harvard study
the MCD equivalent (C5) showed outcomes identical to the
EZB/C3 subgroup (five-year OS 60%). Interestingly, the
HMRN study showed a poor outcome amongst curatively
treated (R-CHOP-like) patients, but this effect was greatly
reduced when the analysis was restricted to cases treated with
full-dose R-CHOP (Fig 7). Thus, the negative outcome in
this subtype may in part reflect an overrepresentation of
older or comorbid patients who are unable to tolerate full-
dose treatment and are therefore generally excluded from
clinical studies. The BN2 subgroup shows an intermediate
outcome in the NCI study (five-year OS 67%), an excellent
outcome in the Harvard study (five-year OS 80%), but a
poor outcome in the HMRN study (five-year OS 55%). The
A53 group showed an intermediate prognosis in both the
NCI and Harvard studies (five-year OS 65%).
In summary, whilst the effect of some groups is clear
(ST2, N1, EZB–MYC), the true prognostic impact of the
other groups remains to be determined in prospective trials.
However, the real value of a genetic classification system does
not lie in its ability to predict response to R-CHOP. Rather
it will be to identify homogeneous groups of tumours with
shared biology that may respond similarly to specific targeted
therapies.
Challenges of implementing molecular
subtyping
Implementing a genomic classifier in clinical practice will be
associated with a number of challenges. Important
Fig 5. A guide and unified colour scheme for the plethora of diffuse large B-cell lymphoma (DLBCL) classification systems. (A) The diagnosis of
DLBCL has grown progressively more complex as we continue to refine methods to delineate cases with distinct pathobiology. Several clinical
entities that share features with DLBCL have been re-defined as distinct entities (column 1). The cell of origin (COO) system has been refined
further to separate cases with gene expression profiles resembling double-hit lymphomas (DHITsig+) or Burkitt lymphoma (MHG) (Column 2).
Columns 3–5 show the relationship between subgroups defined in the three systems discussed in the text. Each of the LymphGen [National Can-
cer Institute (NCI)] and revised Haematological Malignancy Research Network (HMRN) systems include a subgroup defined by activating muta-
tions in NOTCH1. Both the NCI and Harvard systems (but not HMRN) accommodate aneuploid cases with (or without) TP53 mutations. This
figure uses a colour palette that was carefully designed to allow for the consistent representation of the main diagnostic entities, molecular and
genetic classifications for DLBCL. The colour codes and utilities to allow the use of this palette are available as an open-source package at https://
github.com/morinlab/ggsci. (B) Using this colour scheme, we have re-illustrated the data from the HMRN study to show the relationship between
the lymphoma diagnostic entities and the HMRN genetic classes.
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considerations include the type of sequencing required and
choice of classifier to be used (Fig 1). The NCI and Harvard
studies used whole-exome sequencing to identify mutation
and copy number alteration in a combination of fresh frozen
and FFPE biopsies. The HMRN study used a targeted
sequencing panel applied to FFPE biopsies, an approach that
might be more suited to a diagnostic laboratory. Indeed, for
all classifiers the vast majority of information comes from the
genetic status of about 100–150 genes. However, the absence
of genome-wide copy number precludes identification of the
A53 group. Targeted copy number assays or shallow whole-
genome sequencing may ultimately become cost-efficient
ways to identify the A53 group. However, for now, for indi-
vidual research groups, the added value of identifying the
A53 group (66% of patients) will need to be weighed
against the significant increase in sequencing required for
A53 identification.
The choice of classifier is also important. Initial studies
relied upon clustering of large numbers of patients. Translat-
ing this to a single patient is now possible using the NCI
Fig 6. Distinct stages of B-cell differentiation hijacked by subtypes of diffuse large B-cell lymphoma (DLBCL) and related lymphoid malignancies.
The progression of a B cell through the germinal centre is shown including lymphoma types that may originate from each of these stages of dif-
ferentiation. The molecular subclassifications described by the LymphGen, Harvard and HMRN groups are shown, associated with the alternative
lymphoid malignancies they most closely resemble. These include primary central nervous system lymphoma (PCNSL), primary testicular lym-
phoma (PTL), and Waldenstr€om macroglobulinaemia (WM), which most likely derive from a precursor memory B cell and share features with
the MCD subtype. The characteristics of BN2 cases suggest similarity to marginal zone lymphoma (MZL). EZB tumours recapitulate the genetics
of follicular lymphoma (FL), and likely derive from light-zone centrocytes. In contrast, EZB–MYC+ cases most likely arise from dark-zone cen-
troblasts. NOTCH1 mutations, whilst rare in DLBCL, suggest a possible a link to chronic lymphocytic leukaemia (CLL), with either a na€ıve B cell
or precursor memory B cell (MBC) origin. ST2 cases have a genetic signature similar to nodular lymphocyte-predominant Hodgkin lymphoma
(NLPHL) and primary mediastinal large B cell lymphoma (PMBCL) and arise from germinal-centre B cells. The biology and cellular origin of the
A53/C2 subtype remain unclear. The most enriched gene mutations and gene expression signatures are indicated below each subtype.
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LymphGen classifier39 or the code linked to the HMRN
study.40 Importantly the LymphGen classifier is designed to
work with ‘imperfect data’ meaning it can be used for both
targeted or whole-exome sequencing. A further classifier
from the Harvard group has been described in abstract that
relies on just 22 genetic features but is not publicly available.
A recent publication applied the LymphGen classifier to cases
classified in the HMRN study and showed high concordance
with the original HMRN assignment.41 Indeed, the greatest
source of variability was the number of cases classified at all
rather than the movement between subtypes (Fig 5B).
LymphGen assigned a unique classification to 53% of cases,
whereas HMRN classified 73% of cases.41 In contrast, the
Harvard classifier, according to their original clustering
paper, assigns a classification to 96% of cases. These numbers
are clearly very different and raise the important question of
how to judge which provides the most correct answer. Whilst
the general description of individual molecular subgroups is
an area of agreement, precisely where to place the boundaries
around them is not. In the absence of a gold standard refer-
ence this may prove challenging to resolve. The answer will
ultimately come from the ability of a classifier to identify
patient groups that respond to targeted therapies. Until con-
sensus is reached it would seem prudent for clinical trials to
capture as much genetic information as is reasonably practi-
cable in order to employ both existing and future classifiers.
An important source of variability between studies is the
strategy for calling genetic variants. Current classifications
have been constructed based upon a binary call of mutant
versus not-mutant for each gene. However, it is not always
straightforward to determine the significance of an individual
mutation, especially in the absence of germline DNA. Whilst
this is straightforward for driver genes with well-established
hotspot codons like MYD88 L265P, it is more challenging to
interpret the significance of scattered missense mutations in
genes that are subject to somatic hypermutation (SHM).
Whilst not all of these have a lymphoma driver function it
seems clear that patterns of hypermutated genes differ across
subtypes, suggesting these mutations may represent useful
classification markers.73 This question of whether to report
SHM as a genetic marker independent of a driver mutation
role is approached differently in different studies. Examples
of genes with widely different mutation frequencies include
SOCS1, TET2 and BCL2 (Fig 3A). This most likely reflects
different variant filtering strategies. Thus, different variant
calling strategies may provide different outputs even when
the same classifier is used. This may become a more signifi-
cant problem as classifiers attempt to focus onto a smaller
number of classifier genes, where the opportunity to spread
the risk of classifying individual genes is reduced.
It remains likely that a significant number of cases will
not fit into the current genetic subtypes and that further sub-
types remain to be discovered. Given the number of cases of
DLBCL that have been subjected to exome sequencing it
seems less likely that new driver mutations will be discovered
in protein-coding genes. However, the next wave of whole-
genome sequencing may reveal previously undiscovered alter-
ations in non-coding and regulatory regions. A recent exam-
ple is the frequent mutation of the 3ʹUTR of NFKBIZ,
leading to elevated protein expression in ABC DLBCL.74 Fur-
ther such discoveries may reveal new subgroups within the
UC cases or may refine the current classification in a manner
similar to how gene expression profiling has identified a
MYC-driven subgroup of EZB. Advances in technology for
proteomic quantification, assessment of host immune status
or the involvement of viral pathogens in driving lymphoma-
genesis may all contribute new understanding to the chal-
lenge of defining molecular subtypes of DLBCL in coming
years.
Finally, there are logistical considerations associated with
the need for sufficient quantity and quality of biopsy tissue,
and the ability to return sequencing data in a clinically
meaningful timeframe. The recent UK REMoDL-B study
overcame similar challenges for microarray assays and
returned gene expression data within a three-week window
for nationally recruited patients analysed at a central diag-
nostic laboratory.6 We believe a similar approach could be
applied to genetic profiling. Furthermore, advances in circu-
lating tumour DNA technology may ultimately allow DLBCL
genotyping to be performed on a plasma sample.75
Why now is the time to invest in genomic
profiling for DLBCL
It is important to be clear about the potential value of any
form of molecular profiling. Broadly there are three reasons
Fig 7. Comparison of survival outcomes by genetic subtype across
studies. The five-year overall survival is shown for each subtype as
described across their respective publications. Equivalent subtypes
share the colour scheme described in Fig 5. The classification system
used, the relevant published study, treatment received [(cyclophos-
phamide, doxorubicin, vincristine, prednisone + rituximab) (R-
CHOP) versus R-CHOP-like], and number of patients contributing
to survival analysis in each study are shown below the graph.
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to do this: (i) to inform on prognosis; (ii) to allow selection
of optimal therapy; and (iii) to provide a biology-based
framework on which to design and interpret clinical trials.
We have discussed how genomic profiling provides some,
although limited, prognostic information on R-CHOP-
treated DLBCL. Our current understanding of the underlying
biology already allows hypotheses to be generated about
which subgroups may respond to specific therapy. However,
at present these remain hypotheses and it would be prema-
ture to suggest that genomics subtypes can currently be used
to select therapy. Instead, the true value of genomics subtyp-
ing lies in the provision of a biology-based framework on
which to design and interpret DLBCL trials. As discussed at
the start of the review, the most significant barrier to the
introduction of new and targeted therapies to first-line
DLBCL is the considerable biological heterogeneity within
the umbrella of DLBCL. The molecular subtypes discussed
above allow the grouping of cases that share similar biology,
depend on similar oncogenic pathways and therefore may
respond in a similar way to targeted therapies. Stratifying
patients into molecular subtypes will allow us to detect
responses to therapy that may only be seen in a small but
defined molecular subgroup. This may require that we
rethink our clinical trial strategy. We envisage that future tri-
als may follow an adaptive design where novel agents are ini-
tially screened across all DLBCL types but subsequently
focused onto molecular subgroups where a potential response
signal is observed. Our current biological understanding may
allow us to narrow the therapeutic focus already; however
there will always be surprises. An example of this is the
REMoDL-B trial, which randomised first-line DLBCL
patients to R-CHOP plus or minus proteasome inhibition
with bortezomib based on the hypothesis that proteasome
inhibition might benefit ABC DLBCL patients.6 Whist
improved outcome was not seen overall, or in the hypothe-
sised subtype, a trend towards improved progression-free
survival (PFS) was unexpectedly seen in the MHG subgroup
identified by transcriptional profiling27. This result should
now be tested in a formal prospective trial in MHG patients.
As genomic profiling becomes standard in DLBCL we
should heed the lessons learned from our experiences with
COO and FISH profiling. This includes the need for a har-
monised approach, and to resist the temptation for oversim-
plified assays that provide a poor proxy for the true
classification. It also highlights the importance of prospective
studies to determine the true prognostic impact, and for ran-
domised studies to avoid the premature adoption of fashion-
able but unproven subtype-directed therapies.
We consider it is essential to now include molecular pro-
filing in all prospective drug trials in DLBCL. Whether this
should include comprehensive exome and RNA sequencing
or a more focused sequencing strategy is a debate that will
continue. But without some form of genomic testing to
resolve individual molecular subtypes it is unlikely we will
ever deploy novel therapies in DLBCL to their greatest
advantage. As our understanding of the genomics and biol-
ogy of DLBCL progresses we can expect that classification
systems will continue to evolve. The broadest possible
molecular profiling may therefore future-proof trials against
evolution in genetic subtyping. However, we should not let
this delay starting. Indeed, one important aspect of introduc-
ing molecular profiling now will be to overcome the logisti-
cal and infrastructure barriers to returning genomic data in
a clinically meaningful timeframe. To stand a chance of
being effective, biologically-targeted therapies need to be
deployed in a biologically targeted manner. Molecular sub-
typing of DLBCL is the next step in this precision medicine
journey.
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